|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Elimination half-life||14 hours (halazepam), 50–100 hours (metabolites).|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||352.7 g/mol g·mol−1|
|3D model (JSmol)|
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published in June 15, 1998 as follows:
|Onset of action||Intermediate to slow|
|Plasma half life||14 hr for parent drug and 30-100 hr for its metabolite|
|Peak plasma levels||1-3 hr for parent drug and 3-6 hf for its metabolite|
|Metabolism||Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)|
|Excretion||Excreted through kidneys|
|Protein binding||98% bound to plasma protein|
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.
- Quazepam, fletazepam, triflubazam — benzodiazepines with trifluoromethyl group attached
- "halazepam". Drugs.com. Retrieved December 11, 2014.
- "Alapryl". Drugs.com. Retrieved December 11, 2014.
- "Pacinone". Drugs.com. Retrieved December 11, 2014.
- Quitkin, Frederick M. ... (1998). Current therapeutic drugs (2nd ed.). Washington: American Psychiatric Press. p. 166. ISBN 0880489944.
- "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Regulations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.